Background: We analyzed the -y6 T cell composition
, and the major yB T cell subset in the periphery (namely the one expressing Vy9 and V82) proliferates vigorously in vitro to various antigenic preparations of MTB (6, (8) (9) (10) . Several MTB-,y6 T cell antigens have been chemically defined and include nonproteic and/or nucleotide molecules containing critical phosphate moieties (1 1-13) .
The precise role played by Vy9/V82 T cells in human TB is not yet known. Previous studies reported either an increase (14) (15) (16) or no change (17, 18) in y8T cells in the peripheral blood of TB patients. Moreover, a dramatic reduction in Vy9/ V82 T cells was found in TB patients, which were refractory to in vitro stimulation by MTB antigens (19) . Contrasting data have also been obtained from studying y6 T cells at the site of the disease, showing that y8 cells accumulate in TB lymphoadenitis (20) , are not increased in TB granulomas (21) , and are strongly decreased in bronchoalveolar lavage of patients affected by pulmonary TB (19) . These conflicting results may be a consequence of analyzing 'y8 T cells from patients affected by different clinical forms of TB or at different stages of disease progression.
In this report, we analyzed the yS T cell responses in the peripheral blood and in cerebrospinal fluid (CSF) of children affected by TBM, which is a severe form of extrapulmonary TB associated with high mortality. Early diagnosis of TBM in children is life saving but difficult because symptoms are nonspecific. Examination of the CSF may reveal lymphocytosis together with high protein and low glucose concentrations, but these characteristics may also be associated with other diseases such as viral meningitis and purulent meningitis. Delay in diagnosis of TBM is directly related to a poor prognosis, whereas early treatment permits recovery without neurological sequelae. Furthermore, TBM in children is usually due to primary infection (22, 23) Purification of Mycobacterial TUBAgJ TUBAgI was obtained from Mycobacterium fortuitum-secreted antigens. Briefly, 2.5 liters of M. fortuitum biovar fortuitum was grown for 6 weeks as velum on Sauton's medium. Culture medium was collected, filtered, and partitioned twice between chloroform and water. The water phase was concentrated, loaded onto DEAE, and eluted with increasing concentrations of ammonium acetate. The 0.2 M salt fraction was collected, dried three times, and separated on high-performance liquid chromatography (HPLC) C 18 in 0.1 M ammonium acetate. The fractions were collected and tested for bioactivity for the GI 2 y8 T cell clone as described elsewhere (24) . The first active peak was eluted after 1.3 Vo was collected, dried, and reseparated by mobile-phase ion pair HPLC (MPIC-HPLC), using a modification of Di Pierro's method, as already described (25) . TUBAg 1 was further characterized by its Rt upon high-performance anion-exchange chromatog- (26) . After 72 hr, cultures were supplemented with 0.5 ml medium containing 20 U/ml rhIL-2 and every 72 hr, 0.5 ml medium was replaced with 0.5 ml fresh medium containing 20 U/ml rhIL-2 (27 (29) . Total RNA from Ficoll-Hypaque-purified CSF cells was prepared by guanidinium thiocyanate-phenol-chloroform extraction (30) with 10 ,ug of P815 RNA carrier. Single-stranded DNA was synthesized by means of a cDNA synthesis kit (Perkin Elmer, Rome, Italy) and an aliquot of the reaction, corresponding to an equivalent of 4-5 X 103 YS+ CD3+ T cells, was subjected to PCR amplification in a total volume of 50 gl, using the V62 5' primer (5' -AACCTGGCTGTACTTAAGATAC -3') and the C8 antisense primer (5'-CGGATGGTTTGGTAT-GAGGC-3') in saturating conditions as described in Poccia et al. (29) . Two microliters of the V62-C6 PCR reaction was subjected to a cycle of elongation (runoff) in 10 ,ll of reaction buffer containing 3 mM MgCl2 (final concentration) and 0.1 ,uM of one of the fluorescent J6-specific antisense primers (J61 = 5'-XTTCCACAGTCA-CACGGGTTC-3'; J62 = 5' -XTTCCACGATGAGT-TGTGTTCC-3'; J83 = 5'-XCACGAAGAGTTT-GATGCCAG-3', in which X designates the dye bound to the primer through the amino-2 group). Separation and analysis of the runoff products were performed as described previously (31) using an Applied Biosystem 373A DNA sequencer. Dye-labeled size standards were included in each electrophoresis run. This allows for precise determination of the size of each V82/J6 runoff DNA fragment. CDR3, defined in T cell receptors (TCRs) from amino acid residue 95 (located in the V region gene) to amino acid residue 106 (located in the J gene) can thus be easily determined. For the V82 gene segmentspecific oligonucleotide, this corresponds to a distance of 66 nt upstream from residue 95, and for the J6 gene segment-specific oligonucleotides to a distance of 30 nt (for J81 and J62) or 27 nt (for J83) downstream from residue 106. The fluorescence intensity is expressed in arbitrary units TUBAg  160  1400  2  PHA  250  1400  TUBAg  240  1100  3  PHA  140  1100  TUBAg  120  580  4  PHA  200  970  TUBAg  210  840  5  PHA  200  950  TUBAg  170  700  6  PHA  380  1600  TUBAg  450  1800 Vy9/VS2 T cell lines obtained from CSF cells of patients affected by TBM were stimulated in vitro with PHA or TUBAg and TNF-a and IFN--y production assessed by ELISA as described in Materials and Methods.
Effect of Chemotherapy on Vy9/V82 T Cell Responses The Vy9/V82 T cell responses were retested in four patients halfway (approximately 4 months) through chemotherapy. Figure 2A shows that chemotherapy caused a modification of the y6 subsets in CSF, and the percentage of V-y9/V62+ cells decreased nearly to that detected in CSF of control subjects. Parallel to this finding was the V'y9/V82 T cell response to TUBAg, which strongly decreased during drug treatment, both in CSF cells (Fig. 2B ) and PBMC (data not shown).
V82-J8 Junctional Diversity in Vy9/V82 T Cells Isolated from CSF of TBM Patients before and after Chemotherapy
To assess whether the decrease in Vy9/V62 T cells observed in CSF after chemotherapy concerned some specific clones, we analyzed the CDR3 size distribution of V82-J81, V82-J82, and V62-J63 rearrangements of TUBAgl-stimulated CSF cells from four TBM children before and after chemotherapy. As V82-JS2 were rare (data not shown), our analysis focused on V62-J81 and V62-J63 rearrangements. As shown in Figure 3 (27) . Because CD4 T cell anergy is a rather common phenomenon in patients with active pulmonary TB (34) (35) (36) , the possibility remains that the observed V-y9/V62 anergy might be the consequence of primary CD4 T cell anergy. (37) . However, the finding that the Vy9/V82 percentage and responsiveness in CSF decreased after chemotherapy (Fig. 2) while IL-12 levels in CSF remained unchanged or increased (our unpublished observations) argues against this possibility. The above findings raise the question as to whether there is a protective or pathogenic role of Vy9/V82 T cells in TBM. The CSF-derived V,y9/V62 lines produce IFN-'y, which is a cytokine necessary for a protective immune response to MTB infection (38) and may drive differentiation of CD4+ T lymphocytes toward the Thi class. Similarly, TNF-a is a key cytokine involved in granuloma formation and an important cofactor for the induction of IFN-y production (39), but overproduction of this pro-inflammatory cytokine might be crucial for the pathogenesis of meningitis.
The selective increase in V-y9/V82 cells in the CSF of TBM children indicates that they contribute to the immune response. While the decrease in Vy9/Va2 cells during recovery could be interpreted as contributing to pathology, their clear type 1 phenotype also suggests a protective role.
